Perspectives in the Application of Immunocorrector – transfer factor ™ in Immunoprophylaxis Programmes and Immunorehabilitation

Abstract

Background. Human health is largely determined by the body’s resistance to various damagingfactors and, in particular, the functional state of its immune system. The use of unique, new generation immunomodulators in prevention of diseases is promising.Goal of the research was to defne the perspectives in the application of immunocorrector Transfer factorTM in immunoprophylaxis programmes and immunorehabilitation analysing and summarizing scientifc articles.Methods. Systemic literature overview was performed, including 77 scientifc articles and conference proceedings in English, published in the period from 1949 to 2016. The main inclusion criterion was clinical trial or literature review, analysing the effect of immunocorrector on human healthin cases of different disorders.Results. Transfer factors are molecules that communicate antigenic immunological informationintracellularly from a donor to a recipient. Mammalian Transfer factors, including those of humansare small molecules between 3,500 and 10,000 Daltons. Transfer factor’s functions of cell-mediatedimmunity and non-specifc immunological activity differ from the functions of antibodies. Transferfactors are divided into three fractions: the inductors that provide rapid immune response and generalreadiness of the immune system; suppressors, which regulate the intensity of the immune response,preventing allergic and autoimmune reactions; antigen specifc Transfer factors with a set of certainantigens, allowing quick adjusting of the immune system to recognize many bacterial and viruses.Conclusions. Transfer factors have no side effects and are considered as highly effective in treatment of infectious, parasitic, oncological, dermatological, venereal and somatic diseases, so arehighly recommended for preventive purposes and decreasing of aging.

Untitled

“…В связи с этим рекомендуется регулярное употребление пищевых продуктов, стимулирующих аутофагию [95], и препаратов трансферфактора, показавших свою эффективность в качестве средства иммунореабилитации, в т.ч. при терапии неоплазий [96,97].…”